Ushigome, Emi
Kitagawa, Nobuko
Kitagawa, Noriyuki
Tanaka, Toru
Hasegawa, Goji
Ohnishi, Masayoshi
Tsunoda, Sei
Ushigome, Hidetaka
Yokota, Isao
Nakamura, Naoto
Asano, Mai
Hamaguchi, Masahide
Yamazaki, Masahiro
Fukui, Michiaki
Article History
Received: 9 April 2020
Revised: 11 August 2020
Accepted: 13 August 2020
First Online: 7 December 2020
Compliance with ethical standards
:
: EU received grants from the Japan Society for the Promotion of Science and ONO PHARMACEUTICAL CO., LTD. and received personal fees from AstraZeneca plc; Astellas Pharma Inc.; DAIICHI SANKYO COMPANY, LIMITED; Kyowa Hakko Kirin Company Ltd.; KOWA PHARMACEUTICAL COMPANY LTD.; MSD K.K.; Mitsubishi Tanabe Pharma Corp.; Novo Nordisk Pharma Ltd.; Taisho Toyama Pharmaceutical Co., Ltd.; Takeda Pharmaceutical Co., Ltd.; Nippon Boehringer Ingelheim Co., Ltd.; Sumitomo Dainippon Pharma Co., Ltd.; and Johnson & Johnson K.K. outside the submitted work. Masahide Hamaguchi received grants from Asahi Kasei Pharma; Nippon Boehringer Ingelheim Co., Ltd.; Mitsubishi Tanabe Pharma Corporation; DAIICHI SANKYO COMPANY, LIMITED; Sanofi K.K.; Takeda Pharmaceutical Company Limited; Astellas Pharma Inc.; Kyowa Kirin Co., Ltd.; Sumitomo Dainippon Pharma Co., Ltd.; Novo Nordisk Pharma Ltd.; and Eli Lilly Japan K.K. Masahide Hamaguchi also received personal fees from ONO PHARMACEUTICAL CO., LTD.; AstraZeneca plc; KOWA PHARMACEUTICAL COMPANY LTD.; MSD K.K.; Mitsubishi Tanabe Pharma Corp.; and Sumitomo Dainippon Pharma Co., Ltd. outside the submitted work. Masahiro Yamazaki received personal fees from MSD K.K.; Sumitomo Dainippon Pharma Co., Ltd.; Kowa Company, Ltd.; AstraZeneca PLC; Takeda Pharmaceutical Company Ltd.; Kyowa Hakko Kirin Co., Ltd.; DAIICHI SANKYO COMPANY, LIMITED; KOWA PHARMACEUTICAL COMPANY LTD.; and ONO PHARMACEUTICAL CO., LTD. outside the submitted work. Michiaki Fukui received grants from the Japan Society for the Promotion of Science; Nippon Boehringer Ingelheim Co., Ltd.; KISSEI PHARMACEUTICAL CO., LTD.; Mitsubishi Tanabe Pharma Corporation; DAIICHI SANKYO COMPANY, LIMITED; Sanofi K.K.; Takeda Pharmaceutical Company Limited; Astellas Pharma Inc.; MSD K.K.; Kyowa Hakko Kirin Co., Ltd.; Sumitomo Dainippon Pharma Co., Ltd.; KOWA PHARMACEUTICAL COMPANY LTD.; Novo Nordisk Pharma Ltd.; ONO PHARMACEUTICAL CO., LTD.; SANWA KAGAKU KENKYUSHO CO., LTD.; Eli Lilly Japan K.K.; Taisho Pharmaceutical Co., Ltd.; TERUMO CORPORATION; TEIJIN PHARMA LIMITED; Nippon Chemiphar Co., Ltd.; and Johnson & Johnson k.k. Medical Company. Michiaki Fukui also received honoraria from Nippon Boehringer Ingelheim Co., Ltd.; KISSEI PHARMACEUTICAL CO., LTD.; Mitsubishi Tanabe Pharma Corporation; DAIICHI SANKYO COMPANY, LIMITED; Sanofi K.K.; Takeda Pharmaceutical Company Limited; Astellas Pharma Inc.; MSD K.K.; Kyowa Kirin Co., Ltd.; Sumitomo Dainippon Pharma Co., Ltd.; KOWA PHARMACEUTICAL COMPANY LTD.; Novo Nordisk Pharma Ltd.; ONO PHARMACEUTICAL CO., LTD.; SANWA KAGAKU KENKYUSHO CO., LTD.; Eli Lilly Japan K.K.; Taisho Pharmaceutical Co., Ltd.; Bayer Yakuhin, Ltd.; AstraZeneca K.K.; MOCHIDA PHARMACEUTICAL CO., LTD.; and Combi Corporation outside the submitted work. IY received speaking fees from Chugai Pharmaceutical Co., Ltd. and Japan Tobacco Inc. Pharmaceutical Division outside the submitted work. The sponsors were not involved in the study design; in the collection, analysis, or interpretation of the data; in the writing of this manuscript; or in the decision to submit the article for publication. The authors, their immediate families, and any research foundations with which they are affiliated have not received any financial payments or other benefits from any commercial entity related to the subject of this article. The authors declare that although they are affiliated with a department that is supported financially by a pharmaceutical company, the authors received no current funding for this study, and their department affiliation does not alter their adherence to all the full journal policies on sharing data and materials.